TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF NASAL SPRAY MARKET 22
1.4 CURRENCY AND PRICING 23
1.5 LIMITATION 23
1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHIC SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 RESEARCH METHODOLOGY 29
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.7 SECONDARY SOURCES 33
2.8 ASSUMPTIONS 33
3 MARKET OVERVIEW 34
3.1 DRIVERS 36
3.1.1 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 36
3.1.2 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 37
3.1.3 INCREASE IN INFECTION & ALLERGIC CASES 38
3.2 RESTRAINTS 38
3.2.1 PRODUCT RECALLS 38
3.3 OPPORTUNITIES 39
3.3.1 NEW RISING DEMAND FOR SELF ADMINISTRATIVE DRUG DELIVERY 39
3.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 39
3.4 CHALLENGES 40
3.4.1 REGULATORY HURDLES 40
4 EXECUTIVE SUMMARY 41
5 PREMIUM INSIGHTS 45
?
6 GLOBAL NASAL SPRAY MARKET, BY PRODUCT TYPE 48
6.1 OVERVIEW 49
6.2 DECONGESTION NASAL SPRAY 51
6.3 SALT WATER SOLUTION/ SALINE NASAL SPRAY 52
6.4 STEROID NASAL SPRAY 54
6.5 OTHERS 55
7 GLOBAL N ASAL SPRAY MARKET, BY CONTAINER DESIGN 56
7.1 OVERVIEW 57
7.2 PRESSURIZED CANISTERS 59
7.3 PUMP BOTTLES 60
8 GLOBAL NASAL SPRAY MARKET, BY DOSAGE FORM 61
8.1 OVERVIEW 62
8.2 UNIT/SINGLE DOSE 64
8.3 BI DOSE 66
8.4 MULTI DOSE 67
9 GLOBAL NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 69
9.1 OVERVIEW 70
9.2 ANTIHISTAMINE 72
9.3 NASAL STEROIDS 74
9.4 MAST CELL INHIBITOR 75
9.5 ANTICHOLINERGIC 76
10 GLOBAL NASAL SPRAY MARKET, BY APPLICATION 77
10.1 OVERVIEW 78
10.2 ALLERGIC AND NON-ALLERGIC RHINITIS 80
10.3 NASAL CONGESTION 82
10.4 CENTRAL NERVOUS SYSTEM DISORDERS 83
10.5 VACCINATION 84
10.6 OTHERS 85
11 GLOBAL NASAL SPRAY MARKET, BY PRESCRIPTION MODE 86
11.1 OVERVIEW 87
11.2 PRESCRIPTION BASED 89
11.3 OVER THE COUNTER 90
?
12 GLOBAL NASAL SPRAY MARKET, BY END USER 92
12.1 OVERVIEW 93
12.2 HOSPITALS 95
12.3 CLINICS 96
12.4 HOME CARE SETTINGS 97
12.5 COMMUNITY HEALTH CARE 98
13 GLOBAL NASAL SPRAY MARKET, BY GEOGRAPHY 99
13.1 OVERVIEW 100
13.2 NORTH AMERICA 105
13.2.1 INCREASING MANUFACTURING CAPABILITIES IN U.S. 105
13.2.2 U.S. 113
13.2.3 CANADA 117
13.2.4 MEXICO 121
13.3 EUROPE 125
13.3.1 STRICT GOVERNMENT REGULATIONS 125
13.3.2 GERMANY 134
13.3.3 U.K. 138
13.3.4 FRANCE 142
13.3.5 ITALY 146
13.3.6 SPAIN 150
13.3.7 SWITZERLAND 154
13.3.8 NETHERLANDS 158
13.3.9 BELGIUM 162
13.3.10 RUSSIA 166
13.3.11 TURKEY 170
13.3.12 REST OF EUROPE 174
13.4 ASIA-PACIFIC 175
13.4.1 INCREAISNG PREVELENCE OF THE COPD 175
13.4.2 CHINA 184
13.4.3 JAPAN 188
13.4.4 INDIA 192
13.4.5 AUSTRALIA 196
13.4.6 SOUTH KOREA 200
13.4.7 MALAYSIA 204
13.4.8 THAILAND 208
13.4.9 SINGAPORE 212
13.4.10 INDONESIA 216
13.4.11 PHILIPPINES 220
13.4.12 REST OF ASIA PACIFIC 224
13.5 SOUTH AMERICA 225
13.5.1 RISING PREVELANCE OF THE NASAL ALLERGIES IN THE LATIN AMERICA 225
13.5.2 BRAZIL 233
13.5.3 REST OF SOUTH AMERICA 237
13.6 MIDDLE EAST AND AFRICA 238
13.6.1 GROWING PREFERENCES FOR DRUG ADMINISTRATION THROUGH INTRA NASAL ROUTE 238
13.6.2 SOUTH AFRICA 246
13.6.3 REST OF MIDDLE EAST & AFRICA 250
14 GLOBAL NASAL SPRAY MARKET, COMPANY LANDSCAPE 251
14.1 COMPANY SHARE ANALYSIS; GLOBAL 251
14.2 COMPANY SHARE ANALYSIS; NORTH AMERICA 252
14.3 COMPANY SHARE ANALYSIS; EUROPE 253
14.4 COMPANY SHARE ANALYSIS; ASIA-PACIFIC 254
15 COMPANY PROFILE 255
15.1 PFIZER INC. 255
15.1.1 COMPANY OVERVIEW 255
15.1.2 REVENUE ANALYSIS 255
15.1.3 COMPANY SHARE ANALYSIS 256
15.1.4 PRODUCT PORTFOLIO 257
15.1.5 RECENT DEVELOPMENTS 257
15.2 CIPLA INC. 258
15.2.1 COMPANY OVERVIEW 258
15.2.2 REVENUE ANALYSIS 258
15.2.3 COMPANY SHARE ANALYSIS 259
15.2.4 PRODUCT PORTFOLIO 259
15.2.5 RECENT DEVELOPMENTS 260
15.3 BAYER AG 261
15.3.1 COMPANY OVERVIEW 261
15.3.2 REVENUE ANALYSIS 261
15.3.3 COMPANY SHARE ANALYSIS 262
15.3.4 PRODUCT PORTFOLIO 262
15.3.5 RECENT DEVELOPMENTS 262
15.4 INNOVUS PHARMACEUTICALS, INC. 263
15.4.1 COMPANY OVERVIEW 263
15.4.2 REVENUE ANALYSIS 263
15.4.3 COMPANY SHARE ANALYSIS 264
15.4.4 PRODUCT PORTFOLIO 264
15.4.5 RECENT DEVELOPMENTS 264
15.5 GLAXOSMITHKLINE PLC. 265
15.5.1 COMPANY OVERVIEW 265
15.5.2 REVENUE ANALYSIS 265
15.5.3 PRODUCT PORTFOLIO 266
15.5.4 RECENT DEVELOPMENTS 266
15.6 ADAPT PHARMA, INC. 267
15.6.1 COMPANY OVERVIEW 267
15.6.2 GEOGRAPHIC PRESENCE 267
15.6.3 PRODUCT PORTFOLIO 268
15.6.4 RECENT DEVELOPMENTS 268
15.7 AISHWARYA GROUP 269
15.7.1 COMPANY OVERVIEW 269
15.7.2 PRODUCT PORTFOLIO 269
15.7.3 RECENT DEVELOPMENTS 269
15.8 ALLERGAN 270
15.8.1 COMPANY OVERVIEW 270
15.8.2 REVENUE ANALYSIS 270
15.8.3 PRODUCT PORTFOLIO 270
15.8.4 RECENT DEVELOPMENTS 271
15.9 ARIUS FORMULATIONS PVT LTD 272
15.9.1 COMPANY OVERVIEW 272
15.9.2 PRODUCT PORTFOLIO 272
15.9.3 RECENT DEVELOPMENTS 272
15.10 AURENA 273
15.10.1 COMPANY OVERVIEW 273
15.10.2 GEOGRAPHIC PRESENCE 273
15.10.3 PRODUCT PORTFOLIO 274
15.10.4 RECENT DEVELOPMENTS 274
15.11 CATALENT, INC 275
15.11.1 COMPANY OVERVIEW 275
15.11.2 REVENUE ANALYSIS 275
15.11.3 PRODUCT PORTFOLIO 276
15.11.4 RECENT DEVELOPMENTS 276
15.12 EGALET CORPORATION 277
15.12.1 COMPANY OVERVIEW 277
15.12.2 REVENUE ANALYSIS 277
15.12.3 PRODUCT PORTFOLIO 278
15.12.4 RECENT DEVELOPMENTS 278
?
15.13 J PHARMACEUTICALS 279
15.13.1 COMPANY OVERVIEW 279
15.13.2 PRODUCT PORTFOLIO 279
15.13.3 RECENT DEVELOPMENTS 279
15.14 LEEFORD HEALTHCARE LTD 280
15.14.1 COMPANY OVERVIEW 280
15.14.2 GEOGRAPHIC PRESENCE 280
15.14.3 PRODUCT PORTFOLIO 281
15.14.4 RECENT DEVELOPMENTS 281
15.15 MYLAN N.V. 282
15.15.1 REVENUE ANALYSIS 282
15.15.2 PRODUCT PORTFOLIO 283
15.15.3 RECENT DEVELOPMENTS 283
15.16 SANDOZ INTERNATIONAL GMBH 284
15.16.1 COMPANY OVERVIEW 284
15.16.2 GEOGRAPHIC PRESENCE 284
15.16.3 PRODUCT PORTFOLIO 285
15.16.4 RECENT DEVELOPMENTS 285
15.17 ST. RENATUS 286
15.17.1 COMPANY OVERVIEW 286
15.17.2 PRODUCT PORTFOLIO 286
15.17.3 RECENT DEVELOPMENTS 286
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD. 287
15.18.1 COMPANY OVERVIEW 287
15.18.2 REVENUE ANALYSIS 287
15.18.3 PRODUCT PORTFOLIO 288
15.18.4 RECENT DEVELOPMENTS 288
15.19 ULTRATECH INDIA LIMITED 289
15.19.1 COMPANY OVERVIEW 289
15.19.2 PRODUCT PORTFOLIO 289
15.19.3 RECENT DEVELOPMENTS 289
16 RELATED REPORTS 290
?